Obesity News and Research

Latest Obesity News and Research

Insilico and SK Biopharmaceuticals partner to develop AI-driven neuroimmune therapies

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervous system.

22 Jun 2026

Accelerated biological aging may drive rising early-onset cancer risk

Cancer is often considered a disease of aging. Older adults are at higher risk because they have had more time to accumulate cellular damage that can trigger tumor formation.

22 Jun 2026

Optimized proximity labeling platform tracks cellular protein communication networks

The body's organs are in constant communication. Fat tissue tells the liver when to store or release energy, the immune system signals localized inflammation, and thousands of proteins carry these messages to organs throughout the body.

22 Jun 2026

Review outlines how donor imaging improves liver transplantation outcomes

Liver transplantation often depends on decisions made under pressure. In deceased donation, teams must quickly judge whether a liver is suitable, whether fat accumulation could threaten graft function, and whether unexpected vascular anatomy may complicate procurement or implantation.

22 Jun 2026

GLP-1 medications may lower risk of multiple substance use disorders

A new study led by researchers at The University of Texas at El Paso found that use of weight loss drugs like Ozempic and other GLP-1s is associated with a lower risk of developing alcohol, opioid, nicotine and cocaine use disorders.

21 Jun 2026

Many kidney transplant candidates fail to reach the national waitlist

Nearly half of Americans with kidney failure who are referred for transplantation never begin the process required to be considered for a new organ, a new study shows, while less than a fifth actually complete the assessment and get on the waitlist.

21 Jun 2026

Synthetic gut communities reveal how diet rewires the microbiome

Synthetic microbial communities give researchers controlled models for testing how diet reshapes gut microbial ecology, metabolism, and host-relevant responses. The review highlights how SynComs can strengthen causal inference, improve intervention testing, and support future precision nutrition, while noting major challenges in stability, standardization, and ecological realism.

21 Jun 2026

Obesity genes have stronger impact on modern generations

People who carry genetic variations linked to obesity are more likely to be heavier now than individuals with the same variants who were born before the recent obesity epidemic.

18 Jun 2026

Epigenetic drugs improve blood vessel health in obesity and diabetes

People with obesity and type 2 diabetes are at high risk of blood vessel damage. This risk depends not only on the genes a person carries, but also on how they are "read".

18 Jun 2026

Gut microbes may help explain why obesity and type 2 diabetes become harder to reverse

This review describes how gut microbial messengers, including SCFAs, microbiota-modified bile acids, neuroactive metabolites, and extracellular vesicles, may shape obesity and type 2 diabetes through the microbiota-gut-brain axis.

17 Jun 2026

Weight-loss medications lessen the risk of violent criminal behavior

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for diabetes and obesity, but studies have found evidence that the medications may also influence behavior, such as supporting impulse control and reducing substance use and alcohol consumption by potentially interacting with the brain's reward and stress systems.

17 Jun 2026

AI-designed drug for Parkinson's begins first human trial

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969.

17 Jun 2026

Experts outline a multidisciplinary approach to managing clinical obesity

The rapid rise of GLP-1 medications such as semaglutide and tirzepatide has transformed obesity treatment.

17 Jun 2026

Higher BMI raises risk for 19 cancers as global review expands the obesity-cancer link

A major systematic review and meta-analysis links higher BMI to increased risk of 19 cancer types, including leukemia, non-Hodgkin lymphoma, bladder cancer, and glioma, which were not previously recognized in major consensus reports. The study also reveals regional and sex-based variation in cancer risk, with genetic evidence generally supporting many observational links while highlighting the need for more diverse global cohorts.

17 Jun 2026

Tirzepatide activates calorie-burning brown fat to combat obesity

Tirzepatide doesn't just help people lose weight; it also activates brown adipose tissue, representing a major milestone in obesity research, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

16 Jun 2026

Prebiotic fiber supplement reduces harmful gut metabolites and improves liver health

A study conducted at the University of Jyväskylä, Finland, was the first to investigate the effects of prebiotic xylo-oligosaccharides (XOS) on fatty liver in humans.

16 Jun 2026

Study identifies top predictors for weight loss using tirzepatide

One of the largest real-world studies of people taking GLP-1 medications found women, those without pre-existing conditions such as type 2 diabetes and high blood pressure, and behavioral factors such as previously setting a weight goal were the best predictors of total weight loss, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

16 Jun 2026

Gut bacteria may help explain why fatigue appears before illness

A small study of healthy Japanese adults found that fatigue was associated with distinct gut microbiome, microbial gene, and fecal metabolite patterns. The findings suggest fatigue may track with altered microbial energy metabolism and oxidative stress-related functional potential, but larger longitudinal studies are needed to test causality and clinical value.

16 Jun 2026

GLP-1s may improve testosterone levels and sperm quality in men with obesity

GLP‑1s do not harm male hormones or fertility after long-term use, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

15 Jun 2026

Global study links rising obesity to premature heart disease deaths

Researchers are warning that obesity is reshaping the global cardiovascular disease crisis, as trend data covering 204 countries reveal that heart disease now peaks in people aged 50-54 rather than the elderly and increasingly in South Asia, where rates have grown more than three times faster than global averages, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

15 Jun 2026